At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 

These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.

Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 

In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.

To learn more about the topics in this episode: 


Introducing Fierce Biotech's 2024 Fierce 15


Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline


Synthekine hopes new IL-2 will be the high-alpha in a beta class

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 
These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.
Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 
In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercebiotech.com/special-reports/introducing-fierce-biotechs-2024-fierce-15">Introducing Fierce Biotech's 2024 Fierce 15</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/scorpion-snaps-150m-series-c-funds-widen-clinical-plans-cancer-pipeline">Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/aacr-synthekine-hopes-new-il-2-will-be-high-alpha-beta-class">Synthekine hopes new IL-2 will be the high-alpha in a beta class</a> 
</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Where are they now? Catching up with past Fierce 15 honorees

EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting how—despite steadily rising profits year-over-year—devicemakers large and small are still being squeezed by the cost of doing business and waning investor enthusiasm.  

During AdvaMed’s MedTech Conference this month in Toronto, John Babbitt, partner on the life sciences team at EY, chatted with Fierce Medtech’s Conor Hale about the team's findings and shared what he heard from other executive attendees on the pace of M&A, venture capital funding and recent IPOs.  

Babbitt also discussed how the industry is expanding over-the-counter, to stock shelves with consumer-focused products—as well as how a record number of AI approvals from the FDA may be counted on to help address the ever-growing demand for healthcare, amid provider burnout and staff shortages. 

To learn more about the topics in this episode: 
Ceribell CEO Jane Chao explains why now was the time for its upsized IPO
Stryker strikes again, acquiring brain surgery device maker Nico
How will regulators adapt to adaptive AI?
Medtech VC investment held steady in Q2 with $3.3B of deal value: PitchBook
EY's Pulse of the MedTech Industry report 2024

EY recently published their 18th annual Pulse of the MedTech Industry report, highlighting how—despite steadily rising profits year-over-year—devicemakers large and small are still being squeezed by the cost of doing business and waning investor enthusiasm.  
During AdvaMed’s MedTech Conference this month in Toronto, John Babbitt, partner on the life sciences team at EY, chatted with Fierce Medtech’s Conor Hale about the team's findings and shared what he heard from other executive attendees on the pace of M&amp;A, venture capital funding and recent IPOs.  
Babbitt also discussed how the industry is expanding over-the-counter, to stock shelves with consumer-focused products—as well as how a record number of AI approvals from the FDA may be counted on to help address the ever-growing demand for healthcare, amid provider burnout and staff shortages. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/medtech/ceribell-ceo-jane-chao-explains-why-now-was-time-its-upsized-ipo">Ceribell CEO Jane Chao explains why now was the time for its upsized IPO</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/stryker-strikes-again-acquiring-brain-surgery-devicemaker-nico">Stryker strikes again, acquiring brain surgery device maker Nico</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/how-will-regulators-adapt-adaptive-ai">How will regulators adapt to adaptive AI?</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/medtech-vc-investment-held-steady-q2-33b-deal-value-pitchbook">Medtech VC investment held steady in Q2 with $3.3B of deal value: PitchBook</a></li>
<li><a href="https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook">EY's Pulse of the MedTech Industry report 2024</a></li>
</ul>

The pulse of the medtech industry

In this episode, we dive into the world of gene therapy logistics with Cryoport Systems' innovative Elite Ultra Cold shipping system. Mike Dybicz and Khoa Tran are in the hotseat to discuss how their solution addresses critical challenges in transporting temperature-sensitive gene therapies.

The pair explain how Cryoport Elite offers extended hold times, exceeding industry standards to ensure therapy viability during unexpected delays. Here, its unique payload holding system provides consistent cooling without direct dry ice contact, maintaining product integrity throughout transit.

Security is paramount for these high-value therapies. The system allows for re-icing without accessing the payload, reducing tampering risks. Meanwhile, real-time monitoring tracks key metrics such as temperature, pressure and humidity, providing comprehensive visibility during shipping.

Dybicz and Tran also emphasize their collaborative product development approach, working with clients to meet current needs and anticipate future challenges. In addition, they discuss their commitment to sustainability and share insights on upcoming innovations, including the SafePak system and plans to expand the Elite product line.

Catch the full episode for more insights!

In this episode, we dive into the world of gene therapy logistics with Cryoport Systems' innovative Elite Ultra Cold shipping system. Mike Dybicz and Khoa Tran are in the hotseat to discuss how their solution addresses critical challenges in transporting temperature-sensitive gene therapies.
The pair explain how Cryoport Elite offers extended hold times, exceeding industry standards to ensure therapy viability during unexpected delays. Here, its unique payload holding system provides consistent cooling without direct dry ice contact, maintaining product integrity throughout transit.
Security is paramount for these high-value therapies. The system allows for re-icing without accessing the payload, reducing tampering risks. Meanwhile, real-time monitoring tracks key metrics such as temperature, pressure and humidity, providing comprehensive visibility during shipping.
Dybicz and Tran also emphasize their collaborative product development approach, working with clients to meet current needs and anticipate future challenges. In addition, they discuss their commitment to sustainability and share insights on upcoming innovations, including the SafePak system and plans to expand the Elite product line.
Catch the full episode for more insights!

Cryoport Systems unveils its Elite Ultra Cold shipping system, which is designed to address critical needs in gene therapy transportation.

Revolutionizing gene therapy logistics with Cryoport's Elite solution [Sponsored]

The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023. This momentum shows no signs of slowing, as companies continue to push boundaries in neuroscience and psychiatric disease research.

At this year's Fierce Biotech Summit on Oct. 1, pharma staff writer, Fraiser Kansteiner, sat down with a panel of industry leaders to explore the latest trends, groundbreaking discoveries and the next big targets in neuropharmaceuticals.

Joining the conversation were Camille Bendrosian, M.D., chief medical officer at Amylyx; Craig Thompson, CEO of Cerevance; Sara Kenkare-Mitra, Ph.D., president and head of R&D at Alector; and Blake Mandell, co-founder and CEO of Transcend Therapeutics. 

To learn more about the topics in this episode: 
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
PTSD treatment is on the cusp of a paradigm shift. This biotech hopes to Transcend the competition
After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company
Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE

The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023. This momentum shows no signs of slowing, as companies continue to push boundaries in neuroscience and psychiatric disease research.
At this year's Fierce Biotech Summit on Oct. 1, pharma staff writer, Fraiser Kansteiner, sat down with a panel of industry leaders to explore the latest trends, groundbreaking discoveries and the next big targets in neuropharmaceuticals.
Joining the conversation were Camille Bendrosian, M.D., chief medical officer at Amylyx; Craig Thompson, CEO of Cerevance; Sara Kenkare-Mitra, Ph.D., president and head of R&amp;D at Alector; and Blake Mandell, co-founder and CEO of Transcend Therapeutics. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/bristol-myers-squibbs-karuna-buyout-pays-approval-novel-schizophrenia-med-cobenfy">Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/budding-psychiatry-biotech-looks-transcend-ptsd-competition-sample-phase-2-data">PTSD treatment is on the cusp of a paradigm shift. This biotech hopes to Transcend the competition</a></li>
<li><a href="https://www.fiercepharma.com/pharma/jpm24-after-transformational-year-alkermes-moves-pure-play-neuroscience-specialist">After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/merck-re-enters-alzheimers-battle-billion-dollar-cerevance-pact-years-after-dropping-bace">Merck is back in Alzheimer's saddle with $1B-plus Cerevance pact, years after dropping the BACE</a></li>
</ul>

Where are they now? Catching up with past Fierce 15 honorees

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips